Clinical trials: Chronic Kidney Disease, Secondary Hyperparathyroidism
Renal Osteodystrophy
Renal Osteodystrophy: A Fresh Approach
There are two major goals of this project: 1. Comparison of DXA and QCT for diagnosis of bone loss in CKD-5 patients and determination of the prevalence of low bone turnover in CKD-5 patients with bone loss. 2.
- Trial name
- NCT00859612
- Where
- United States
- Volunteers
- 464 people
- Sponsor
- Hartmut Malluche, MD
Chronic Kidney Disease
Different Effects of Non-calcium Phosphate Binders on Serum Calcium
Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium, and hormones regulating mineral-bone…
- Trial name
- NCT03451019
- Testing
- Sevelamer Hydrochloride, Lanthanum Carbonate
- Where
- Poland
- Volunteers
- 34 people
- Sponsor
- Medical University of Lodz
Hyperparathyroidism, Arterial Stiffness
Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
Active parathyroid glands among renal dialysis patients contribute to calcified and hardened blood vessels. Such damage to the blood vessels, in turn, takes a significant toll in terms of cardiovascular disease.
- Trial name
- NCT01143987
- Testing
- Cinacalcet
- Where
- Hong Kong
- Volunteers
- 44 people
- Sponsor
- Chinese University of Hong Kong
Hyperparathyroidism, Secondary
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
- Trial name
- NCT01785849
- Testing
- Etelcalcetide
- Where
- 118 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National…
- Trial name
- NCT00135304
- Testing
- Sensipar®, Vitamin D
- Volunteers
- 170 people
- Sponsor
- Amgen
Hemodyalysis, Kidney Tansplant
Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general…
- Conditions
- Hemodyalysis, Kidney Tansplant, Osteoporosis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT07141043
- Where
- Romania
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.
Hyperparathyroidism, Secondary
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis
This study evaluates the metabolic and clinical results of two well recognized and accepted surgical techniques in the management of severe hyperparathyroidism in patients under regular dialysis treatment.
- Trial name
- NCT02464072
- Testing
- Subtotal Parathyroidectomy, Total Parathyroidectomy + 45 autografts, Total Parathyroidectomy + 90 autografts
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- University of Sao Paulo General Hospital
Osteopenia, Bone Metabolism Disorders
Effects of Aerobic Versus Resistance Training on Bone Metabolism in Stage 3-4 Chronic Kidney Disease
This randomized controlled trial investigates the comparative effects of aerobic versus resistance training on bone mineral density (BMD) and bone metabolism markers in patients with stage 3 or 4 chronic kidney disease (CKD).
- Conditions
- Osteopenia, Bone Metabolism Disorders, Chronic Kidney Disease (Stage 3-4), Mineral and Bone Disorder (CKD-MBD)
- Trial name
- CKD-BONE-EX (NCT07133256)
- Testing
- Resistance Exercise, Aerobic Training
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sinai University
ESRD
Pharmacoepidemiological Study of Secondary Hyperparathyroidism in Lorraine
The pharmacoepidemiological EPHEYL (Étude PHarmacoÉpidémiologique de l'hYperparathyroïdie secondaire en Lorraine) study is a 2-year, open-cohort, prospective, observational study on incident SHPT, i.e.
- Trial name
- EPHEYL (NCT02888639)
- Volunteers
- 305 people
- Sponsor
- Central Hospital, Nancy, France
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active…
- Trial name
- NCT07122401
- Testing
- MT1013, Cinacalcet
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
Paricalcitol capsules (Zemplar®) received marketing authorization in Sweden in late 2007 for the prevention and treatment of secondary hyperparathyroidism in patients with Stage 3 \& 4 Chronic Kidney Disease (CKD).
- Trial name
- CAPITOL (NCT01265992)
- Where
- 10 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease Mineral and Bone Disorder
Phosphate Assessment in Chronic Kidney Disease Patients Study
The proposed pilot feeding study aims to explore novel pathways in phosphate metabolism and identify new biomarkers, as well as to develop a compound index for assessing phosphate overload with high validity and reliability.
- Trial name
- PACK (NCT07368946)
- Testing
- Dietary Phosphorus Intake
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
- Trial name
- NCT01290029
- Testing
- Cinacalcet
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Amgen
Chronic Kidney Disease
Paricalcitol Injection Phase II Trial
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal…
- Trial name
- NCT00646932
- Testing
- paricalcitol
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.
- Trial name
- NCT01506947
- Testing
- Paricalcitol, Darbepoetin alfa
- Volunteers
- 65 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Secondary Hyperparathyroidism, End Stage Renal Disease
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
- Trial name
- NCT00053547
- Testing
- paricalcitol injection
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Abbott
Chronic Kidney Disease, Secondary Hyperparathyroidism
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with…
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
- Trial name
- NCT01219855
- Testing
- Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- OPKO Health, Inc.
Chronic Renal Insufficiency, Renal Osteodystrophy
Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
Patients with chronic renal insufficiency usually develop secondary osteoporosis or bone loss, which is called renal osteodystrophy.
- Trial name
- NCT02147782
- Where
- 4 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine